<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Anaphylaxis_%28peds%29</id>
	<title>Anaphylaxis (peds) - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Anaphylaxis_%28peds%29"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;action=history"/>
	<updated>2026-04-18T10:09:56Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=389143&amp;oldid=prev</id>
		<title>Danbot: Strip excess bold</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=389143&amp;oldid=prev"/>
		<updated>2026-03-22T09:28:00Z</updated>

		<summary type="html">&lt;p&gt;Strip excess bold&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 09:28, 22 March 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l81&quot;&gt;Line 81:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 81:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Management==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Management==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;[[Epinephrine]]&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Epinephrine]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**1:1000 '''IM''' 0.3 - 0.5mg (0.3 - 0.5mL) every 5 - 15 minutes&amp;lt;ref&amp;gt;Dhami S. et al. Management of anaphylaxis: a systematic review. Allergy. 69 (2014) 168–175. http://onlinelibrary.wiley.com/store/10.1111/all.12318/asset/all12318.pdf?v=1&amp;amp;t=hrspdbpk&amp;amp;s=8067bfd5903c7ffebf4a274f062a71633ebe0507&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Sheikh A, Shehata YA, Brown SGA, Simons FER. '''Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.''' ''Cochrane Database of Systematic Reviews'' 2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**1:1000 '''IM''' 0.3 - 0.5mg (0.3 - 0.5mL) every 5 - 15 minutes&amp;lt;ref&amp;gt;Dhami S. et al. Management of anaphylaxis: a systematic review. Allergy. 69 (2014) 168–175. http://onlinelibrary.wiley.com/store/10.1111/all.12318/asset/all12318.pdf?v=1&amp;amp;t=hrspdbpk&amp;amp;s=8067bfd5903c7ffebf4a274f062a71633ebe0507&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Sheikh A, Shehata YA, Brown SGA, Simons FER. '''Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.''' ''Cochrane Database of Systematic Reviews'' 2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Give as soon as possible&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Give as soon as possible&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Always IM initially &amp;lt;ref&amp;gt;Simons FER, Gu X, Simons KJ. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;[[Epinephrine]]absorption in adults: Intramuscular versus subcutaneous injection,&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;''' &lt;/del&gt;''J Allergy Clin Immunol'' 2001;108:871-3 &amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Always IM initially &amp;lt;ref&amp;gt;Simons FER, Gu X, Simons KJ. [[Epinephrine]]absorption in adults: Intramuscular versus subcutaneous injection, ''J Allergy Clin Immunol'' 2001;108:871-3 &amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**If response to IM is inadequate: give epinephrine infusion 1:10,000 2 - 10 µg/min&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**If response to IM is inadequate: give epinephrine infusion 1:10,000 2 - 10 µg/min&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;How to make a quick epinephrine drip:&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;''' &lt;/del&gt;''Take your code-cart epinephrine (it does not matter if it is 1:1,000 or 1:10,000) and inject 1mg into a liter bag of NS.  Final concentration is 1mcg/ml.  Run at 1cc/min and titrate to effect''.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**How to make a quick epinephrine drip: ''Take your code-cart epinephrine (it does not matter if it is 1:1,000 or 1:10,000) and inject 1mg into a liter bag of NS.  Final concentration is 1mcg/ml.  Run at 1cc/min and titrate to effect''.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Pediatric: [[Epinephrine]] &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;1:1000 0.01mg/kg (max 0.5mg) IM&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;''' &lt;/del&gt;every 5 to 15 minutes&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Pediatric: [[Epinephrine]] 1:1000 0.01mg/kg (max 0.5mg) IM every 5 to 15 minutes&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**IV infusion: 0.05 - 1 mcg/kg/min&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**IV infusion: 0.05 - 1 mcg/kg/min&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;Supplemental oxygen&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Supplemental oxygen&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**''Consider [[Intubation|endotracheal intubation]] if airway edema present''&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**''Consider [[Intubation|endotracheal intubation]] if airway edema present''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;Normal saline bolus&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Normal saline bolus&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**If unresponsive to [[epinephrine]] assume distributive [[Shock|shock]] and give 1 - 2 liters of normal saline&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**If unresponsive to [[epinephrine]] assume distributive [[Shock|shock]] and give 1 - 2 liters of normal saline&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;Also consider&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Also consider&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**[[Albuterol]] for bronchospasm resistant to IM epinephrine&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**[[Albuterol]] for bronchospasm resistant to IM epinephrine&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**[[Antihistamines]] (for symptom control AFTER hemodynamically stable)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**[[Antihistamines]] (for symptom control AFTER hemodynamically stable)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l107&quot;&gt;Line 107:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 107:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***If taking beta-blocker AND unresponsive to [[Epi|epinephrine]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***If taking beta-blocker AND unresponsive to [[Epi|epinephrine]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Consider adding additional pressor support if persistent hypotension present&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**Consider adding additional pressor support if persistent hypotension present&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***For example: &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;[[vasopressin]]&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;''' &lt;/del&gt;2-8 units for persistent refractory shock (case series only)&amp;lt;ref&amp;gt;Schummer et al. The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock. Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 620-624.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Dünser et al. Treatment of Anaphylactic Shock: Where Is the Evidence? Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 359-361&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***For example: [[vasopressin]] 2-8 units for persistent refractory shock (case series only)&amp;lt;ref&amp;gt;Schummer et al. The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock. Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 620-624.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Dünser et al. Treatment of Anaphylactic Shock: Where Is the Evidence? Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 359-361&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***[[Norepinephrine]] 0.05 to 0.5 mcg/kg per minute&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;***[[Norepinephrine]] 0.05 to 0.5 mcg/kg per minute&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Danbot</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=382715&amp;oldid=prev</id>
		<title>Ostermayer at 21:00, 17 January 2026</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=382715&amp;oldid=prev"/>
		<updated>2026-01-17T21:00:13Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:00, 17 January 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Peds top&lt;/del&gt;}}&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Anaphylaxis]].''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;PediatricPage|Anaphylaxis&lt;/ins&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Background==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Background==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] that is either severe in nature or having two or more organ systems  involved.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] that is either severe in nature or having two or more organ systems  involved.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Ostermayer</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=372919&amp;oldid=prev</id>
		<title>Rossdonaldson1 at 17:31, 11 March 2024</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=372919&amp;oldid=prev"/>
		<updated>2024-03-11T17:31:31Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 17:31, 11 March 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{Peds top}}Anaphylaxis &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;(peds)&lt;/del&gt;.''&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{Peds top}}&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[&lt;/ins&gt;Anaphylaxis&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/ins&gt;.''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Background==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Background==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] that is either severe in nature or having two or more organ systems  involved.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] that is either severe in nature or having two or more organ systems  involved.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Rossdonaldson1</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=372918&amp;oldid=prev</id>
		<title>Rossdonaldson1: Created page with &quot;{{Peds top}}Anaphylaxis (peds).'' ==Background== *Type I hypersensitivity reaction that is either severe in nature or having two or more organ systems  involved. *Clinically Anaphylaxis and its treatment is virtually identical whether it is the traditional IgE dependent anaphylaxis reaction (vast majority), or the IgE independent ''anaphylactoid'' reaction *Precipitants **Food (most common) **Medications **Insect stings **Latex **Aerobic...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Anaphylaxis_(peds)&amp;diff=372918&amp;oldid=prev"/>
		<updated>2024-03-11T17:30:37Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;{{Peds top}}Anaphylaxis (peds).&amp;#039;&amp;#039; ==Background== *Type I &lt;a href=&quot;/wiki/Hypersensitivity_Reaction&quot; class=&quot;mw-redirect&quot; title=&quot;Hypersensitivity Reaction&quot;&gt;hypersensitivity reaction&lt;/a&gt; that is either severe in nature or having two or more organ systems  involved. *Clinically &lt;a href=&quot;/wiki/Anaphylaxis&quot; title=&quot;Anaphylaxis&quot;&gt;Anaphylaxis&lt;/a&gt; and its treatment is virtually identical whether it is the traditional IgE dependent anaphylaxis reaction (vast majority), or the IgE independent &amp;#039;&amp;#039;anaphylactoid&amp;#039;&amp;#039; reaction *Precipitants **Food (most common) **Medications **Insect stings **Latex **Aerobic...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Peds top}}Anaphylaxis (peds).''&lt;br /&gt;
==Background==&lt;br /&gt;
*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] that is either severe in nature or having two or more organ systems  involved.&lt;br /&gt;
*Clinically [[Anaphylaxis]] and its treatment is virtually identical whether it is the traditional IgE dependent anaphylaxis reaction (vast majority), or the IgE independent ''anaphylactoid'' reaction&lt;br /&gt;
*Precipitants&lt;br /&gt;
**Food (most common)&lt;br /&gt;
**Medications&lt;br /&gt;
**Insect stings&lt;br /&gt;
**Latex&lt;br /&gt;
**Aerobic exercise&lt;br /&gt;
**Idiopathic (rare)&lt;br /&gt;
&lt;br /&gt;
==Clinical Features==&lt;br /&gt;
[[File:Hives2010.jpg|thumbnail|Raised [[urticaria]]]]&lt;br /&gt;
[[File:Angioedema2013.jpg|thumbnail|[[Angioedema]] of tongue]]&lt;br /&gt;
[[File:Angioedema2010.jpg|thumb|Angioedema of face.]]&lt;br /&gt;
*Cutaneous symptoms (90%)&lt;br /&gt;
**[[Hives]]&lt;br /&gt;
**[[Angioedema]]&lt;br /&gt;
**Itching&lt;br /&gt;
**Morbilliform rash&lt;br /&gt;
*Respiratory symptoms (70%)&lt;br /&gt;
**[[Wheezing]]&lt;br /&gt;
**[[Shortness of breath]]&lt;br /&gt;
**Throat itching or tightness&lt;br /&gt;
**Hoarseness&lt;br /&gt;
**Stridor&lt;br /&gt;
**Hypoxia, cyanosis&lt;br /&gt;
*Gastrointestinal symptoms (40%)&lt;br /&gt;
**Abdominal pain&lt;br /&gt;
**Nausea, vomiting&lt;br /&gt;
**[[Diarrhea]]&lt;br /&gt;
*Cardiovascular symptoms (35%)&lt;br /&gt;
**[[Hypotension]]&lt;br /&gt;
**Chest pain&lt;br /&gt;
**Palpitations&lt;br /&gt;
*Central Nervous System&lt;br /&gt;
**Uneasiness &lt;br /&gt;
**Altered mental status&lt;br /&gt;
**Headache, dizziness, confusion&lt;br /&gt;
**Syncope&lt;br /&gt;
&lt;br /&gt;
===Expected Course===&lt;br /&gt;
====Uniphasic (80-90%)====&lt;br /&gt;
*Symptoms peak within 30 minutes to 1 hour after onset, resolve within 30 minutes to 1 hour of receiving treatment&amp;lt;ref&amp;gt;Ewan PW. '''ABC of allergies – Anaphylaxis,''' ''BMJ'' 1998; 316: 1442-1445 &amp;lt;/ref&amp;gt;&lt;br /&gt;
====Biphasic (10-20%)====&lt;br /&gt;
''Biphasic reactions are rare and can occur anywhere from 10 minutes up to six days after an initial reaction.''&amp;lt;ref&amp;gt; Milne K. Biphasic Allergic Reactions: Observation, Treatment Guidelines http://www.acepnow.com/article/biphasic-allergic-reactions-observation-treatment-guidelines/&amp;lt;/ref&amp;gt;&lt;br /&gt;
*Uniphasic response, followed by asymptomatic period of hour or more, then return of symptoms&lt;br /&gt;
*The second phase does not necessarily resemble the first!&lt;br /&gt;
*More likely with a severe initial presentation or repeated epinephrine doses. Additionally hypotension, widened pulse pressure, unknown trigger, and drug trigger in children&amp;lt;ref&amp;gt;Ellis AK, Day JH: Incidence and characteristics of biphasic anaphylaxis: A prospective evaluation of 103 patients. Ann Allergy Asthma Immunology. 2007; 98:64-69&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;aaaai&amp;quot;/&amp;gt;&lt;br /&gt;
*Little evidence to support the use of discharge steroids to prevent a biphasic reaction&lt;br /&gt;
*0.4% of patients with anaphylaxis had a rebound event while in the ED&amp;lt;ref name=&amp;quot;biphasic&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Differential Diagnosis==&lt;br /&gt;
{{Acute Allergic DDX}}&lt;br /&gt;
{{Shock DDX}}&lt;br /&gt;
{{Erythematous rash DDX}}&lt;br /&gt;
&lt;br /&gt;
==Evaluation==&lt;br /&gt;
''[[Anaphylaxis]] is highly likely when ANY ONE of the following criteria is fulfilled''&amp;lt;ref&amp;gt;Brown SGA, Mullins RJ and Gold MS. '''Anaphylaxis: diagnosis and management,''' ''MJA'' 2006; 185: 283–289  &amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Lieberman P et al. '''The diagnosis and management of anaphyalxis: An updated practice parameter,''' ''J Allergy Clin Immunol'' 2005;115;3:S483-S523 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Criterion 1 (90% of patients)===&lt;br /&gt;
*Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:&lt;br /&gt;
**Respiratory Compromise&lt;br /&gt;
**Reduced blood pressure or associated symptoms ([[Syncope]], [[Dizziness]])&lt;br /&gt;
&lt;br /&gt;
===Criterion 2 (10-20% of patients)===&lt;br /&gt;
*TWO OR MORE of the following that occur rapidly after exposure to a LIKELY allergen for that patient&lt;br /&gt;
**Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula)&lt;br /&gt;
**Respiratory compromise&lt;br /&gt;
**[[Reduced BP|Hypotension]] or associated symptoms &lt;br /&gt;
**Persistent gastrointestinal symptoms: ([[Vomiting|vomiting]], [[Diarrhea|diarrhea]], crampy [[Abd Pain|abdominal pain]])&lt;br /&gt;
&lt;br /&gt;
===Criterion 3===&lt;br /&gt;
*[[Reduced BP|Hypotension]] after exposure to a KNOWN allergy for that patient (minutes to hours):&lt;br /&gt;
**Adults: systolic blood pressure (SBP) &amp;lt;90 mmHg or &amp;gt;30% reduction from baseline&lt;br /&gt;
**Pediatrics&lt;br /&gt;
***1 month - 1 year: SBP &amp;lt;70 mmHg&lt;br /&gt;
***1 year - 10 years: SBP &amp;lt;(70 mmHg + [2 x age])&lt;br /&gt;
***11 years - 17 years: SBP &amp;lt;90 mmHg&lt;br /&gt;
&lt;br /&gt;
==Management==&lt;br /&gt;
*'''[[Epinephrine]]'''&lt;br /&gt;
**1:1000 '''IM''' 0.3 - 0.5mg (0.3 - 0.5mL) every 5 - 15 minutes&amp;lt;ref&amp;gt;Dhami S. et al. Management of anaphylaxis: a systematic review. Allergy. 69 (2014) 168–175. http://onlinelibrary.wiley.com/store/10.1111/all.12318/asset/all12318.pdf?v=1&amp;amp;t=hrspdbpk&amp;amp;s=8067bfd5903c7ffebf4a274f062a71633ebe0507&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Sheikh A, Shehata YA, Brown SGA, Simons FER. '''Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.''' ''Cochrane Database of Systematic Reviews'' 2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2&amp;lt;/ref&amp;gt;&lt;br /&gt;
**Give as soon as possible&lt;br /&gt;
**Always IM initially &amp;lt;ref&amp;gt;Simons FER, Gu X, Simons KJ. '''[[Epinephrine]]absorption in adults: Intramuscular versus subcutaneous injection,''' ''J Allergy Clin Immunol'' 2001;108:871-3 &amp;lt;/ref&amp;gt;&lt;br /&gt;
**If response to IM is inadequate: give epinephrine infusion 1:10,000 2 - 10 µg/min&lt;br /&gt;
**'''How to make a quick epinephrine drip:''' ''Take your code-cart epinephrine (it does not matter if it is 1:1,000 or 1:10,000) and inject 1mg into a liter bag of NS.  Final concentration is 1mcg/ml.  Run at 1cc/min and titrate to effect''.&lt;br /&gt;
*Pediatric: [[Epinephrine]] '''1:1000 0.01mg/kg (max 0.5mg) IM''' every 5 to 15 minutes&lt;br /&gt;
**IV infusion: 0.05 - 1 mcg/kg/min&lt;br /&gt;
*'''Supplemental oxygen'''&lt;br /&gt;
**''Consider [[Intubation|endotracheal intubation]] if airway edema present''&lt;br /&gt;
*'''Normal saline bolus'''&lt;br /&gt;
**If unresponsive to [[epinephrine]] assume distributive [[Shock|shock]] and give 1 - 2 liters of normal saline&lt;br /&gt;
*'''Also consider'''&lt;br /&gt;
**[[Albuterol]] for bronchospasm resistant to IM epinephrine&lt;br /&gt;
**[[Antihistamines]] (for symptom control AFTER hemodynamically stable)&lt;br /&gt;
***[[Diphenhydramine]]: 25 to 50mg IV (1mg/kg in children)&lt;br /&gt;
***[[Ranitidine]]: 50mg IV (0.5mg/kg in children) (has been found to improve urticaria but not angioedema at 2 hours&amp;lt;ref&amp;gt;Lin, RY et al. Improved Outcomes in Patients With Acute  Allergic Syndromes Who Are Treated With  Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.&amp;lt;/ref&amp;gt;)&lt;br /&gt;
***AVOID promethazine as this can worsen hypotension&lt;br /&gt;
**Glucocorticoid&lt;br /&gt;
***MAY blunt biphasic reaction although little evidence to support usage&amp;lt;ref&amp;gt;Choo KJ, Simons E, Sheikh A: Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65:1205-1211.&amp;lt;/ref&amp;gt;&lt;br /&gt;
***[[Methylprednisolone]]: 125mg IV (2mg/kg in children)&lt;br /&gt;
***[[Dexamethasone]]: 10mg IV or PO (0.6mg/kg in children)&lt;br /&gt;
**[[Glucagon]]&lt;br /&gt;
***1 - 5mg IV over 5 minutes followed by infusion of 5 - 15 µg/min&amp;lt;ref&amp;gt;Campbell RL, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014; 113:599e608.&amp;lt;/ref&amp;gt;&lt;br /&gt;
***If taking beta-blocker AND unresponsive to [[Epi|epinephrine]]&lt;br /&gt;
**Consider adding additional pressor support if persistent hypotension present&lt;br /&gt;
***For example: '''[[vasopressin]]''' 2-8 units for persistent refractory shock (case series only)&amp;lt;ref&amp;gt;Schummer et al. The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock. Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 620-624.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Dünser et al. Treatment of Anaphylactic Shock: Where Is the Evidence? Anesthesia &amp;amp; Analgesia: August 2008 - Volume 107 - Issue 2 - pp 359-361&amp;lt;/ref&amp;gt;&lt;br /&gt;
***[[Norepinephrine]] 0.05 to 0.5 mcg/kg per minute&lt;br /&gt;
&lt;br /&gt;
==Disposition==&lt;br /&gt;
===Admit===&lt;br /&gt;
*Severe and moderate presentations, especially if symptoms did not respond promptly to epinephrine or required repeat dosing&lt;br /&gt;
*Labs that may be requested by allergist/admitting team if uncertain diagnosis&lt;br /&gt;
**Histamine level - serum elevation 30-60 min following anaphylaxis, window easily missed&lt;br /&gt;
**Tryptase - peaks at 2-4 hrs, remains elevated 6-12 hrs&lt;br /&gt;
&lt;br /&gt;
===Discharge===&lt;br /&gt;
*Consider discharge after 1 hour observation, if no severe symptoms and no repeat epinephrine doses (AAAAI recommendations)&amp;lt;ref name=&amp;quot;aaaai&amp;quot;&amp;gt;Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082. https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Professional%20Education/Podcasts/Anaphylaxis-2020-grade-document.pdf&amp;lt;/ref&amp;gt;&lt;br /&gt;
**NPV of 1-hour observation was 95%, with NPV for biphasic anaphylaxis after &amp;gt;6 hours of observation of 97.3% &amp;lt;ref&amp;gt;Shaker M, Wallace D, Golden DBK, Oppenheimer J, Greenhawt M. Simulation of health and economic benefits of extended observation of resolved anaphylaxis. JAMA Netw Open 2019;2:e1913951.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*Send home with an [[epinephrine]] autoinjector! (Epi-Pen)&lt;br /&gt;
**Up to 6% of the people with anaphylaxis have a repeat ED visit for anaphylaxis within 7 days&amp;lt;ref name=&amp;quot;biphasic&amp;quot;&amp;gt;Grunau BE et al. Incidence of Clinically Important Biphasic Reactions in Emergency Department Patients With Allergic Reactions or Anaphylaxis. Ann Emerg Med. 2013 Nov 13&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
*[[Allergic Reaction]]&lt;br /&gt;
*[[Angioedema]]&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Critical Care]]&lt;/div&gt;</summary>
		<author><name>Rossdonaldson1</name></author>
	</entry>
</feed>